In some patients, aggressive cancers can become resistant to chemotherapy and radiation treatments.
In a paper published in Nature Communications, University of California, San Diego School of Medicine researchers identified a pathway that causes the resistance and a new therapeutic drug that targets this pathway.
“It was previously known that RAF (a family of proteins that regulate cellular signalling) governs resistance to therapies. We discovered an undescribed role for RAF and learned precisely how it occurs in a broad range of cancers,” said lead author Sunil Advani, MD, assistant professor in the Department of Radiation Medicine and Applied Sciences. ∞∞∞∞∞ ecancer.org ∞∞∞∞∞